E J Feldman

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. doi request reprint Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?
    E J Feldman
    Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th Street, New York, NY 10021, USA
    Curr Hematol Malig Rep 7:74-7. 2012
  2. doi request reprint Farnesyltransferase inhibitors in myelodysplastic syndrome
    E J Feldman
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Curr Hematol Malig Rep 1:20-4. 2006
  3. doi request reprint On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
    E J Feldman
    Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10021, USA
    Leukemia 22:1707-11. 2008
  4. ncbi request reprint Monoclonal antibody therapy in acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Curr Hematol Rep 2:73-7. 2003
  5. ncbi request reprint The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate
    Eric Feldman
    The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, NY, USA
    Exp Hematol 31:702-7. 2003
  6. doi request reprint First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA
    J Clin Oncol 29:979-85. 2011
  7. ncbi request reprint Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
    J Clin Oncol 23:4110-6. 2005
  8. doi request reprint Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
    Eric J Feldman
    Weill Cornell Medical College, NY 10021, USA
    Best Pract Res Clin Haematol 24:523-6. 2011
  9. ncbi request reprint Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy
    K Seiter
    Department of Medicine, Division of Oncology/Hematology, New York Medical College, New York, NY, USA
    Leukemia 15:963-70. 2001
  10. ncbi request reprint Farnesyltransferase inhibitors in myelodysplastic syndrome
    E J Feldman
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Curr Hematol Rep 4:186-90. 2005

Detail Information

Publications32

  1. doi request reprint Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation?
    E J Feldman
    Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th Street, New York, NY 10021, USA
    Curr Hematol Malig Rep 7:74-7. 2012
    ....
  2. doi request reprint Farnesyltransferase inhibitors in myelodysplastic syndrome
    E J Feldman
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Curr Hematol Malig Rep 1:20-4. 2006
    ....
  3. doi request reprint On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
    E J Feldman
    Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10021, USA
    Leukemia 22:1707-11. 2008
    ..Gastrointestinal toxicity was significant with 19% of patients discontinuing therapy due to diarrhea, nausea and/or anorexia. Lonafarnib has demonstrable activity in patients with advanced MDS and CMML...
  4. ncbi request reprint Monoclonal antibody therapy in acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Curr Hematol Rep 2:73-7. 2003
    ..Whether the use of these antibodies in combination with, or as a substitute for, currently available therapy will lead to improved outcomes for patients with acute myeloid leukemia has not been demonstrated to date...
  5. ncbi request reprint The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate
    Eric Feldman
    The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, NY, USA
    Exp Hematol 31:702-7. 2003
    ..To describe clinical and laboratory features of a cohort of patients with chronic myelogenous leukemia (CML) who developed Ph(-), trisomy 8(+) metaphases while on treatment with imatinib mesylate...
  6. doi request reprint First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 East 68th St, New York, NY 10021, USA
    J Clin Oncol 29:979-85. 2011
    ..This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351...
  7. ncbi request reprint Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
    Eric J Feldman
    Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
    J Clin Oncol 23:4110-6. 2005
    ..In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)...
  8. doi request reprint Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
    Eric J Feldman
    Weill Cornell Medical College, NY 10021, USA
    Best Pract Res Clin Haematol 24:523-6. 2011
    ..This discussion provides some insight, based primarily on two published retrospective reviews of the German cooperative groups, into the question of whether t-AML is an independent adverse variable...
  9. ncbi request reprint Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy
    K Seiter
    Department of Medicine, Division of Oncology/Hematology, New York Medical College, New York, NY, USA
    Leukemia 15:963-70. 2001
    ..Spontaneous resolution of some changes and prolonged persistence of others in the absence of hematologic disease indicates that some cytogenetic changes are not sufficient to promote leukemogenesis...
  10. ncbi request reprint Farnesyltransferase inhibitors in myelodysplastic syndrome
    E J Feldman
    Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Curr Hematol Rep 4:186-90. 2005
    ..Despite this, significant clinical efficacy of the FTIs in MDS, on par with that of currently available chemotherapeutic agents, has been observed, leading to further development of this new class of drugs in MDS and AML...
  11. ncbi request reprint Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome
    G J Roboz
    Leukemia Program, Weill Medical College of Cornell University The New York Presbyterian Hospital, New York, NY, USA
    Leukemia 20:952-7. 2006
    ..In conclusion, the MTD of PTK/ZK is 750 mg orally b.i.d. The drug is generally well tolerated and can be given in combination with chemotherapy for patients with MDS and AML...
  12. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  13. ncbi request reprint Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia
    G J Roboz
    Division of Hematology and Oncology, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 43:1951-5. 2002
    ..In conclusion, in patients with relapsed/refractory AML, gemtuzumab ozogamicin has a comparable response rate to single-agent chemotherapy and may offer a more favorable toxicity profile...
  14. doi request reprint Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
    E J Feldman
    Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA
    Leuk Res 36:1283-9. 2012
    ..The unique pharmacologic features of CPX-351 contribute to its promising antileukemic efficacy...
  15. doi request reprint Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
    P Martin
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Ann Oncol 19:1327-30. 2008
    ..We evaluated outcomes from a single-center cohort managed in a more traditional fashion...
  16. ncbi request reprint Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma
    Gail J Roboz
    Division of Hematology Oncology, Leukemia Program, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 31:1141-4. 2007
    ..Our findings suggest that the potential risk of these important complications must be considered in the development of this novel therapeutic strategy in the first-line setting...
  17. ncbi request reprint Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results
    John P Leonard
    Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 10:5327-34. 2004
    ..We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma...
  18. doi request reprint Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 113:2504-11. 2008
    ..In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low-dose cytarabine in untreated patients aged >or=60 years with AML...
  19. ncbi request reprint A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy
    Tsiporah Shore
    Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York 10021, USA
    Biol Blood Marrow Transplant 12:868-75. 2006
    ....
  20. ncbi request reprint Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia
    Gail J Roboz
    Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 25:10-5. 2007
    ....
  21. doi request reprint Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
    Gail J Roboz
    Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Res 35:522-5. 2011
    ..Mortality within the first 4 weeks was 8%. The regimen was active and had a tolerable extramedullary toxicity profile, but it was cumbersome and intensive compared to other currently available treatments...
  22. ncbi request reprint Activation of FGFR1beta signaling pathway promotes survival, migration and resistance to chemotherapy in acute myeloid leukemia cells
    M A Karajannis
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leukemia 20:979-86. 2006
    ..These data suggest that activation of FGF-2/FGFR1beta supports progression and chemoresistance in subsets of AML. Therefore, FGFR1 targeting may be of therapeutic benefit in subsets of AML...
  23. pmc Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia
    B Psaila
    Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College, New York, NY, USA
    J Thromb Haemost 9:2302-10. 2011
    ..Severe thrombocytopenia is a major risk factor for hemorrhage, but platelet function and bleeding risk at low platelet counts are poorly understood, because of the limitations of platelet function testing at very low platelet counts...
  24. ncbi request reprint Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
    John C Byrd
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus 43210 1240, USA
    Blood 100:4325-36. 2002
    ....
  25. ncbi request reprint Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma
    John D Roberts
    Massey Cancer Center, Virginia Commonwealth University, Medical College of Virginia, Richmond, USA
    Clin Lymphoma 3:184-8. 2002
  26. ncbi request reprint Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:1091-6. 2003
    ..Grade 3 or 4 toxicities included stomatitis (4%), hand-foot syndrome (18%), and skin rash (12%). Four patients (13%) responded. Troxacitabine-based combinations merit study in IM-resistant CML...
  27. ncbi request reprint A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia
    Mitch Raponi
    Veridex, 3210 Merryfield Row, La Jolla, CA 92121, USA
    Blood 111:2589-96. 2008
    ..Therefore, these data indicate that a 2-gene expression assay may have utility in categorizing a population of patients with AML who are more likely to respond to tipifarnib...
  28. ncbi request reprint Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma
    John D Roberts
    Massey Cancer Center, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA 23298, USA
    Clin Cancer Res 12:5809-16. 2006
    ..We undertook a phase I study to identify appropriate schedules and doses of bryostatin 1 and fludarabine to be used in phase II studies...
  29. doi request reprint Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107
    Meir Wetzler
    Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 49:1274-8. 2008
    ..Although the combination of oblimersen and IM is safe and feasible, we did not observe clinical benefit in these patients with imatinib-resistant CML using these doses and schedule...
  30. pmc A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
    Jeffrey E Lancet
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Blood 109:1387-94. 2007
    ..Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response...
  31. ncbi request reprint PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 31:891-7. 2007
    ..One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM...
  32. ncbi request reprint Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Azra Raza
    Rush University Medical Center, Chicago, IL, USA
    Blood 111:86-93. 2008
    ..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...